Recursion Pharmaceuticals, Inc.

Informe acción NasdaqGS:RXRX

Capitalización de mercado: US$1.8b

Recursion Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de Recursion Pharmaceuticals disminuyan en un 1.9% al año, mientras que se espera que sus ingresos anuales crezcan en un 23% al año. Se prevé que el BPA crezca en un 10.3% por año. Se espera que la rentabilidad financiera sea de -168.1% en 3 años.

Información clave

-1.9%

Tasa de crecimiento de los beneficios

10.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs27.3%
Tasa de crecimiento de los ingresos23.0%
Rentabilidad financiera futura-168.1%
Cobertura de analistas

Good

Última actualización07 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Recent updates

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 01

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 24

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Jun 14

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22
Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09
What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Mar 01
We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:RXRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2026104-380-221-2705
12/31/202563-465-365-3378
12/31/202469-397-311-2989
6/30/202450-375-346-332N/A
3/31/202446-354-331-317N/A
12/31/202345-328-300-288N/A
9/30/202347-293-277-258N/A
6/30/202350-260-266-240N/A
3/31/202347-249-273-234N/A
12/31/202240-239-121-84N/A
9/30/202229-247-134-100N/A
6/30/202218-234-113-78N/A
3/31/202213-212-75-50N/A
12/31/202110-186-198-159N/A
9/30/202110-147-129-89N/A
6/30/20219-124-106-75N/A
3/31/20216-99-84-58N/A
12/31/20204-87-52-45N/A
12/31/20192-62-61-57N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que RXRX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que RXRX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que RXRX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (23% al año) de RXRX crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (23% al año) de RXRX crezcan más rápidamente que un 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: RXRX se prevé que no sea rentable en 3 años.


Descubre empresas en crecimiento